1. Home
  2. BTDR vs IMNM Comparison

BTDR vs IMNM Comparison

Compare BTDR & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BTDR

Bitdeer Technologies Group

HOLD

Current Price

$9.35

Market Cap

3.0B

Sector

Technology

ML Signal

HOLD

Logo Immunome Inc.

IMNM

Immunome Inc.

HOLD

Current Price

$27.40

Market Cap

2.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BTDR
IMNM
Founded
2021
2006
Country
Singapore
United States
Employees
N/A
N/A
Industry
EDP Services
Medicinal Chemicals and Botanical Products
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.0B
2.5B
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
BTDR
IMNM
Price
$9.35
$27.40
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
10
10
Target Price
$22.70
$32.80
AVG Volume (30 Days)
12.2M
947.6K
Earning Date
05-11-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
51.40
EPS
N/A
N/A
Revenue
N/A
$6,941,000.00
Revenue This Year
$72.51
N/A
Revenue Next Year
$40.84
$1,127.34
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.04
$8.67
52 Week High
$27.80
$28.62

Technical Indicators

Market Signals
Indicator
BTDR
IMNM
Relative Strength Index (RSI) 39.44 67.11
Support Level $7.49 $19.28
Resistance Level $9.60 N/A
Average True Range (ATR) 1.18 1.43
MACD -0.01 0.26
Stochastic Oscillator 19.82 80.46

Price Performance

Historical Comparison
BTDR
IMNM

About BTDR Bitdeer Technologies Group

Bitdeer Technologies Group is principally engaged in the provision of digital asset mining services. The Company does not conduct any substantive operations on its own but conducts its primary operations through its subsidiaries. Its majority business segments are: proprietary mining, cloud hash rate sharing and cloud hosting. The company operates five proprietary mining datacenters in the United States and Norway, Bhutan and Singapore.

About IMNM Immunome Inc.

Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.

Share on Social Networks: